Design and development of new anti-HIV agents based on quinolone Scaffolds

HIV infection is a major challenge to humanity, with no cure or a vaccine. The virus is constantly evolving and developing resistance against existing therapies. This motivated us to adopt an intelligent way to target two HIV-1 enzymes (Reverse transcriptase and Integrase) with one drug. Using computational methods, we fused the inhibitory requirements for both enzymes in one scaffold. I synthesized 160 new molecules and tested against HIV-1. Tested molecules did not show inhibition, a few of them showed good potential against lung cancer cells. This opens an exciting avenue for the repurposing of these molecules in the future.